Aethlon Medical
NASDAQ: AEMDSan Diego, US · Nevada corporation
Biotech
Founders & leadership
JB
James B. FrakesExecutive Officer, Director
RS
RODNEY S. KENLEYExecutive Officer, Director
FS
FRANKLYN S. BARRY, JR.Director
RH
RICHARD H. TULLIS, PhDExecutive Officer
JA
JAMES A. JOYCEExecutive Officer, Director
CS
CHETAN SHAH, MDDirector
CS
Chetan S. Shah, M.D.Director
EG
Edward G. BroennimanDirector
NG
Nicolas GikakisDirector
AR
Angela RossettiDirector
Reported raises · per SEC filings
Form D private placements▶$2.2MraisedDec 2025 · 1 investors · BiotechnologyRule 506(b)
▶$2.2MraisedDec 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chetan S. Shah, M.D.Director
- James B. FrakesExecutive Officer, Director
- Edward G. BroennimanDirector
- Nicolas GikakisDirector
- Angela RossettiDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Sales commissions
- $214.5K
- First sale
- Dec 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2.7MraisedJan 2020 · 7 investors · BiotechnologyRule 506(b)
▶$2.7MraisedJan 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- TIMOTHY C. RODELLExecutive Officer, Director
- SABRINA MARTUCCI JOHNSONDirector
- EDWARD G. BROENNIMANDirector
- CHARLES J. FISHERDirector
- CHETAN S. SHAHDirector
- JAMES B. FRAKESExecutive Officer
- GUY CIPRIANIDirector
- Offering amount
- $2.7M
- Amount sold
- $2.7M
- Sales commissions
- $226.2K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2020
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$6MraisedJul 2015 · 19 investors · BiotechnologyRule 506(b)
▶$6MraisedJul 2015 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- RODNEY S. KENLEYExecutive Officer, Director
- FRANKLYN S. BARRY, JR.Director
- JAMES B. FRAKESExecutive Officer
- EDWARD G. BROENNIMANDirector
- RICHARD H. TULLIS, PhDExecutive Officer
- JAMES A. JOYCEExecutive Officer, Director
- CHETAN SHAH, MDDirector
- Offering amount
- $6M
- Amount sold
- $6M
- Sales commissions
- $360.5K
- Placement agents
- ROTH Capital Partners, LLC
- First sale
- Jun 2015
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $298.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $299.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.